Carisma Therapeutics to Present at Upcoming Conferences
Needham 23rd Annual Virtual Healthcare Conference
Steven Kelly , President and Chief Executive Officer, will give a corporate presentation.Wednesday, April 10 at3:45 PM ET - Virtual
Chardan 8th Annual Genetic Medicines & Cell Therapy Manufacturing Summit
Steven Kelly , President and Chief Executive Officer, will give a corporate presentation.Monday, April 29 at2:00 PM ET - Virtual
Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following each event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Head of Investor Relations
[email protected]
Media Contact:
(763) 350-5223
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302106448.html
SOURCE Carisma Therapeutics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PRG Real Estate's Brandon Pierce Earns National Recognition as NAA + HD Supply Maintenance Legends Finalist
- Phoenix Energy CEO Adam Ferrari Receives 2026 Young Alumni Achievement Award from University of Illinois
- Investor Relations and Fundraising Strategist Liana Zavo Brings “Shark Tank on Steroids” Roadshow Model to New York City and Global Markets
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share